T cell-selective deletion of Oct1 protects animals from autoimmune neuroinflammation while maintaining neurotropic pathogen response
Open Access
- 3 July 2019
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 16 (1) , 1-11
Abstract
Treatments for autoimmune diseases aim to dampen autoreactivity while preserving normal immune function. In CD4+ T cells, the transcription factor Oct1/Pou2f1 is a dispensable transcription factor for T cell development and response to primary infection, but promotes expression of target genes, including Il2 and Ifng, under conditions of antigen reencounter. As a result, they are more strongly expressed upon secondary stimulation. Such repeated antigen encounters occur in memory recall responses, in autoimmunity where self-antigen can be recognized multiple times, and in chronic infection where foreign antigen is persistent. Based on these previous findings, we hypothesized that Oct1 loss would protect animals from autoimmunity but maintain normal responses to pathogens in the CNS. We used a conditional mouse Oct1 (Pou2f1) allele and a CD4-Cre driver to determine the effect of T cell-specific Oct1 loss on autoimmune- and viral-induced neuroinflammation using an autoantigen-driven EAE model of autoimmunity and a JHMV model of viral infection. Oct1 conditional deletion mitigated clinical scores and reduced infiltrating T cells and cytokine production in the EAE model. Consistently, Oct1-deficient CD4+ T cells stimulated in vitro showed increased expression of markers associated with T cell anergy, particularly in the absence of co-stimulatory signals. In contrast, anti-viral T cell effector functions are intact in the absence of Oct1, with no changes in neuroinflammation, infiltrating T cells or cytokine production. Our findings uncover a significant difference between the effect of Oct1 loss on autoimmune and anti-pathogen responses, which potentially could be exploited for therapeutic benefit.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01NS041249)
- National Institute of Allergy and Infectious Diseases (R01AI100873)
- Praespero foundation (grant)
- National Multiple Sclerosis Society (FG 201050-A-1)
- Collaborative MS Research Center (CA-1607-25040)
- Ray & Tye Noorda (grant)
- McCarthey Family Foundation (grant)
This publication has 45 references indexed in Scilit:
- Arthritogenic Self-Reactive CD4+ T Cells Acquire an FR4hiCD73hi Anergic State in the Presence of Foxp3+ Regulatory T CellsThe Journal of Immunology, 2012
- Oct1 Is a Switchable, Bipotential Stabilizer of Repressed and Inducible Transcriptional StatesJournal of Biological Chemistry, 2011
- CXCL10 and trafficking of virus-specific T cells during coronavirus-induced demyelinationAutoimmunity, 2009
- Interleukin-12 (IL-12), but Not IL-23, Deficiency Ameliorates Viral Encephalitis without Affecting Viral ControlJournal of Virology, 2009
- Autoimmune T cell responses in the central nervous systemNature Reviews Immunology, 2009
- The Role of ICOS in Directing T Cell Responses: ICOS-Dependent Induction of T Cell Anergy by Tolerogenic Dendritic CellsThe Journal of Immunology, 2009
- Generation of a Protective T-Cell Response Following Coronavirus Infection of the Central Nervous System Is Not Dependent on IL-12/23 SignalingViral Immunology, 2008
- Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?Brain, 2005
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationJournal of Experimental Medicine, 2005
- Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivoImmunity, 1994